Form 4: Enveric Biosciences Executive Peter J. Facchini Reports Changes in Beneficial Ownership

Peter J. Facchini, Chief Innovation Officer of Enveric Biosciences, reports acquisition and disposal of common stock and restricted stock units.

Summary

• Peter J. Facchini, Chief Innovation Officer of Enveric Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On May 8, 2025, Facchini acquired 24,717 shares of common stock and disposed of 33,058 shares.
• The acquisition represents restricted stock units (RSUs) granted under the company's 2020 Long-Term Incentive Plan.
• The RSUs vest over four years, with one-fourth vesting after one year and the remainder vesting monthly thereafter, contingent upon continued employment.
• The reported amounts have been adjusted to reflect a reverse stock split that occurred on January 29, 2025, where every 15 shares were reclassified as one share.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The grant of RSUs to the Chief Innovation Officer aligns his interests with the long-term success of the company.

Risks

• The vesting of RSUs is contingent upon continued employment, creating a potential risk if the executive leaves the company before full vesting.

Future Outlook

The vesting schedule of the RSUs extends over four years, indicating a long-term incentive for the executive.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions.

Key Dates

Keywords

Form 4, Beneficial Ownership, Enveric Biosciences, ENVB, Restricted Stock Units, RSUs, Reverse Stock Split, Peter J. Facchini, Chief Innovation Officer